EyePoint, Inc. Common Stock EYPT
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T02:58:10.304Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-12-18
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T00:59:24.726278662Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-12T02:57:36.415368+00:00
EyePoint, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 2.19 | 374.5% | 516.2% | |||
| 25Δ | 1.71 | 355.7% | 385.4% | |||
| 30Δ | 1.23 | 336.9% | 254.6% | |||
| 35Δ | 0.87 | 292.7% | 153.8% | |||
| 40Δ | 0.61 | 224.5% | 81.5% | |||
| 45Δ | ||||||
| 50Δ | ||||||
| 55Δ | 0.59 | 231.6% | 16.3% | |||
| 60Δ | 0.91 | 256.2% | 14.0% | |||
| 65Δ | 1.24 | 280.8% | 11.8% | |||
| 70Δ | ||||||
| 75Δ | ||||||
| 80Δ | ||||||
20Δ
- Pseudo strike
- 2.19
- IV
- 374.5%
- B/E move
- 516.2%
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- 1.71
- IV
- 355.7%
- B/E move
- 385.4%
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- 1.23
- IV
- 336.9%
- B/E move
- 254.6%
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- 0.87
- IV
- 292.7%
- B/E move
- 153.8%
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- 0.61
- IV
- 224.5%
- B/E move
- 81.5%
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 0.59
- IV
- 231.6%
- B/E move
- 16.3%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 0.91
- IV
- 256.2%
- B/E move
- 14.0%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.24
- IV
- 280.8%
- B/E move
- 11.8%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 286.09% | |
| 328.18% | |
| 212.79% | |
| 178.34% | |
| 193.70% | |
| 244.17% | |
| 340.84% | |
| 352.91% |
Biotechnology
FATE
Description unavailable
More →FDMT
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops candidate products using its adeno-associated virus vectors. The company is headquartered in…
More →FENC
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops candidate products for use in the treatment of cancer in the United States. The company is headquartered in…
More →FLNA
FuelNation Inc., a development stage company, engages in the purchase, transportation, storage, and resale of petroleum products. The company is headquartered in West Palm Beach,…
More →FTRE
Fortrea Holdings Inc. provides clinical development and patient access solutions to the life sciences industry. The company is headquartered in Durham, North Carolina.
More →FULC
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products to improve the lives of patients with genetically defined diseases in areas…
More →